| Primary |
| Drug Use For Unknown Indication |
100.0% |
|
|
| Secondary |
| Drug Use For Unknown Indication |
23.7% |
| Type 2 Diabetes Mellitus |
19.2% |
| Hypertension |
11.0% |
| Product Used For Unknown Indication |
11.0% |
| Diabetes Mellitus |
10.7% |
| Hyperuricaemia |
2.9% |
| Pain |
2.6% |
| Disseminated Tuberculosis |
1.9% |
| Pyrexia |
1.9% |
| Unevaluable Event |
1.9% |
| Parkinson's Disease |
1.6% |
| Deep Vein Thrombosis |
1.3% |
| Diabetes Mellitus Non-insulin-dependent |
1.3% |
| Dyslipidaemia |
1.3% |
| Epilepsy |
1.3% |
| Extrapyramidal Disorder |
1.3% |
| Gout |
1.3% |
| Hypercholesterolaemia |
1.3% |
| Micturition Disorder |
1.3% |
| Diarrhoea |
1.0% |
|
| Renal Failure Acute |
24.6% |
| Vomiting |
21.5% |
| Anaemia Haemolytic Autoimmune |
4.6% |
| Cutaneous Vasculitis |
4.6% |
| Hypoglycaemia |
4.6% |
| Diarrhoea |
3.1% |
| Hepatic Failure |
3.1% |
| Hepatitis |
3.1% |
| Locked-in Syndrome |
3.1% |
| Nausea |
3.1% |
| Otitis Externa |
3.1% |
| Pleurisy |
3.1% |
| Pyrexia |
3.1% |
| Rash Scarlatiniform |
3.1% |
| Renal Impairment |
3.1% |
| Sudden Death |
3.1% |
| Adenocarcinoma Pancreas |
1.5% |
| Brain Oedema |
1.5% |
| Cytolytic Hepatitis |
1.5% |
| Diabetic Nephropathy |
1.5% |
|
| Concomitant |
| Product Used For Unknown Indication |
19.1% |
| Type 2 Diabetes Mellitus |
14.5% |
| Drug Use For Unknown Indication |
14.4% |
| Hypertension |
10.9% |
| Diabetes Mellitus |
10.0% |
| Rheumatoid Arthritis |
8.6% |
| Prophylaxis |
4.7% |
| Atrial Fibrillation |
2.1% |
| Lung Neoplasm Malignant |
1.9% |
| Hypercholesterolaemia |
1.7% |
| Pain |
1.7% |
| Hepatitis C |
1.6% |
| Psoriasis |
1.3% |
| Hiv Infection |
1.2% |
| Lymphoma |
1.2% |
| Non-hodgkin's Lymphoma |
1.2% |
| Depression |
1.0% |
| Hypothyroidism |
1.0% |
| Insulin-requiring Type Ii Diabetes Mellitus |
1.0% |
| Chronic Hepatitis C |
0.9% |
|
| Thrombocytopenia |
10.0% |
| Pyrexia |
8.3% |
| Transaminases Increased |
6.7% |
| Vasculitis |
6.7% |
| Weight Increased |
6.7% |
| Vomiting |
5.8% |
| Pulmonary Embolism |
5.0% |
| Somnolence |
5.0% |
| Toxic Skin Eruption |
5.0% |
| Urinary Retention |
5.0% |
| Weight Decreased |
5.0% |
| Hyponatraemia |
4.2% |
| Malaise |
4.2% |
| Nausea |
4.2% |
| Hepatic Enzyme Increased |
3.3% |
| Renal Failure Acute |
3.3% |
| Transient Ischaemic Attack |
3.3% |
| Tremor |
3.3% |
| Blood Glucose Increased |
2.5% |
| Bronchitis |
2.5% |
|
| Interacting |
| Ill-defined Disorder |
13.6% |
| Osteomyelitis |
13.6% |
| Diabetes Mellitus Non-insulin-dependent |
9.1% |
| Hypertension |
9.1% |
| Loin Pain |
9.1% |
| Osteitis |
9.1% |
| Pain |
9.1% |
| Type 2 Diabetes Mellitus |
9.1% |
| Cerebrovascular Accident Nos |
4.5% |
| Gastrooesophageal Reflux Disease |
4.5% |
| Hypertension Arterial |
4.5% |
| Supplementation Therapy |
4.5% |
|
| Drug Interaction |
33.3% |
| Myoclonus |
33.3% |
| Renal Failure Acute |
33.3% |
|
